We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Read MoreHide Full Article
Key Takeaways
Amvuttra drives Alnylam's top line through expanded label and as patients switch from Onpattro.
Givlaari, Oxlumo and royalties from Leqvio add incremental revenues and global growth potential.
Rare disease drugs delivered $125.7M in first-quarter 2026 revenues, up 15% year over year.
Alnylam Pharmaceuticals’ (ALNY - Free Report) primary top-line driver is its newest drug, Amvuttra (vutrisiran), which is approved in the United States and the EU for treating the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis and ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Amvuttra generated $889.9 million in global sales in the first quarter of 2026, representing 187% year-over-year growth. The figure accounted for 76% of Alnylam’s total revenues generated in the quarter. The drug’s solid uptake has been driven by increased patient demand, mainly in ATTR-CM patients in the United States, as well as several patients switching from Onpattro (patisiran), ALNY’s first FDA-approved drug for hATTR amyloidosis.
Alnylam also markets several other products across the rare disease and cardiovascular markets, providing the company with incremental revenues that add to the top line.
Givlaari (givosiran) is approved in both the United States and the EU for treating adults with acute hepatic porphyria. In the EU, the drug is also approved for use in adolescents. Strong uptake has made Givlaari a meaningful revenue driver, with regulatory filings in additional territories pending or planned during 2026 and beyond to widen its global presence.
Similarly, Oxlumo (lumasiran) injection was initially approved in the United States and the EU for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Later, the drug’s label was expanded to include lowering urinary and plasma oxalate levels. This expansion, coupled with pending or planned regulatory filings in additional territories, strengthens its potential for international growth.
Alnylam also markets a fifth drug, Leqvio (inclisiran), in collaboration with Novartis (NVS - Free Report) to treat hypercholesterolemia in the EU. In the United States, it is approved to reduce low-density lipoprotein cholesterol. The drug’s label has also been expanded to cover high-risk cardiovascular patients, and late-stage studies are underway to broaden its indication further. ALNY earns royalties from Novartis for Leqvio sales that add to the top line.
In the first quarter of 2026, Alnylam generated $125.7 million in net product revenues from its rare disease portfolio (Givlaari and Oxlumo), reflecting a 15% year-over-year increase. Expanding global adoption of these therapies is expected to sustain Alnylam’s top-line growth while diversifying its revenue streams and reducing reliance on Amvuttra.
Pipeline Assets Could Broaden ALNY’s Growth Drivers
Beyond its marketed products, Alnylam’s pipeline offers multiple opportunities to further diversify its commercial portfolio over the long term. The company stands to earn royalties from cemdisiran, which is being advanced by Regeneron across several complement-mediated diseases and is already under regulatory review for generalized myasthenia gravis in the United States.
Alnylam is also progressing mivelsiran into mid-stage studies for Alzheimer’s disease and cerebral amyloid angiopathy, expanding its reach into neurodegenerative disorders. In cardiovascular disease, zilebesiran is being evaluated in a late-stage outcomes study, in partnership with Roche, which could unlock a significant hypertension market opportunity. Meanwhile, nucresiran, a next-generation RNAi therapy for ATTR amyloidosis, has entered phase III development in both polyneuropathy and cardiomyopathy indications.
ALNY’s Competition in the Market for Its Lead Drug
Alnylam’s push to broaden indications and expand the global reach of its marketed drugs is becoming increasingly critical as Amvuttra faces intensifying competition in the ATTR-CM market. Rival therapies, including Pfizer’s (PFE - Free Report) Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s (BBIO - Free Report) Attruby (acoramidis), are already approved and competing for market share in this space.
Vyndaqel is one of the key in-line products that has driven improvement in Pfizer’s revenues in the first quarter of 2026. Global Vyndaqel family revenues of $1.6 billion rose 8% year over year in the quarter, primarily driven by international growth on the back of higher demand due to increases in diagnosis and treatment rates. Pfizer’s Vyndaqel family includes global revenues from Vyndaqel as well as revenues for Vyndamax in the United States and Vynmac in Japan.
Approved in late 2024, Attruby is BridgeBio’s only marketed product. The drug generated sales worth $180.6 million in the first quarter of 2026, up significantly year over year, driven by solid uptake. BridgeBio is also currently evaluating acoramidis for the prevention of early-stage variant transthyretin amyloidosis in a late-stage study.
ALNY’s Stock Price, Valuation and Estimates
Shares of Alnylam have plunged 30.1% so far this year compared with the industry’s 1.8% decline. The stock has also underperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.
ALNY Stock Price Movement
Image Source: Zacks Investment Research
From a valuation standpoint, Alnylam stock is expensive. Going by the price/sales ratio, the company’s shares currently trade at 8.97 trailing 12-month sales per share, higher than 2.30 for the industry. However, the stock is trading much below its five-year mean of 18.24.
ALNY Stock Valuation
Image Source: Zacks Investment Research
Estimates for Alnylam’s 2026 earnings have improved from $9.10 to $9.22 per share in the past 60 days, while estimates for 2027 earnings have deteriorated from $14.66 to $13.68 over the same timeframe.
View the Zacks #1 Rank List
Image: Bigstock
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Key Takeaways
Alnylam Pharmaceuticals’ (ALNY - Free Report) primary top-line driver is its newest drug, Amvuttra (vutrisiran), which is approved in the United States and the EU for treating the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis and ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Amvuttra generated $889.9 million in global sales in the first quarter of 2026, representing 187% year-over-year growth. The figure accounted for 76% of Alnylam’s total revenues generated in the quarter. The drug’s solid uptake has been driven by increased patient demand, mainly in ATTR-CM patients in the United States, as well as several patients switching from Onpattro (patisiran), ALNY’s first FDA-approved drug for hATTR amyloidosis.
Alnylam also markets several other products across the rare disease and cardiovascular markets, providing the company with incremental revenues that add to the top line.
Givlaari (givosiran) is approved in both the United States and the EU for treating adults with acute hepatic porphyria. In the EU, the drug is also approved for use in adolescents. Strong uptake has made Givlaari a meaningful revenue driver, with regulatory filings in additional territories pending or planned during 2026 and beyond to widen its global presence.
Similarly, Oxlumo (lumasiran) injection was initially approved in the United States and the EU for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Later, the drug’s label was expanded to include lowering urinary and plasma oxalate levels. This expansion, coupled with pending or planned regulatory filings in additional territories, strengthens its potential for international growth.
Alnylam also markets a fifth drug, Leqvio (inclisiran), in collaboration with Novartis (NVS - Free Report) to treat hypercholesterolemia in the EU. In the United States, it is approved to reduce low-density lipoprotein cholesterol. The drug’s label has also been expanded to cover high-risk cardiovascular patients, and late-stage studies are underway to broaden its indication further. ALNY earns royalties from Novartis for Leqvio sales that add to the top line.
In the first quarter of 2026, Alnylam generated $125.7 million in net product revenues from its rare disease portfolio (Givlaari and Oxlumo), reflecting a 15% year-over-year increase. Expanding global adoption of these therapies is expected to sustain Alnylam’s top-line growth while diversifying its revenue streams and reducing reliance on Amvuttra.
Pipeline Assets Could Broaden ALNY’s Growth Drivers
Beyond its marketed products, Alnylam’s pipeline offers multiple opportunities to further diversify its commercial portfolio over the long term. The company stands to earn royalties from cemdisiran, which is being advanced by Regeneron across several complement-mediated diseases and is already under regulatory review for generalized myasthenia gravis in the United States.
Alnylam is also progressing mivelsiran into mid-stage studies for Alzheimer’s disease and cerebral amyloid angiopathy, expanding its reach into neurodegenerative disorders. In cardiovascular disease, zilebesiran is being evaluated in a late-stage outcomes study, in partnership with Roche, which could unlock a significant hypertension market opportunity. Meanwhile, nucresiran, a next-generation RNAi therapy for ATTR amyloidosis, has entered phase III development in both polyneuropathy and cardiomyopathy indications.
ALNY’s Competition in the Market for Its Lead Drug
Alnylam’s push to broaden indications and expand the global reach of its marketed drugs is becoming increasingly critical as Amvuttra faces intensifying competition in the ATTR-CM market. Rival therapies, including Pfizer’s (PFE - Free Report) Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s (BBIO - Free Report) Attruby (acoramidis), are already approved and competing for market share in this space.
Vyndaqel is one of the key in-line products that has driven improvement in Pfizer’s revenues in the first quarter of 2026. Global Vyndaqel family revenues of $1.6 billion rose 8% year over year in the quarter, primarily driven by international growth on the back of higher demand due to increases in diagnosis and treatment rates. Pfizer’s Vyndaqel family includes global revenues from Vyndaqel as well as revenues for Vyndamax in the United States and Vynmac in Japan.
Approved in late 2024, Attruby is BridgeBio’s only marketed product. The drug generated sales worth $180.6 million in the first quarter of 2026, up significantly year over year, driven by solid uptake. BridgeBio is also currently evaluating acoramidis for the prevention of early-stage variant transthyretin amyloidosis in a late-stage study.
ALNY’s Stock Price, Valuation and Estimates
Shares of Alnylam have plunged 30.1% so far this year compared with the industry’s 1.8% decline. The stock has also underperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.
ALNY Stock Price Movement
From a valuation standpoint, Alnylam stock is expensive. Going by the price/sales ratio, the company’s shares currently trade at 8.97 trailing 12-month sales per share, higher than 2.30 for the industry. However, the stock is trading much below its five-year mean of 18.24.
ALNY Stock Valuation
Estimates for Alnylam’s 2026 earnings have improved from $9.10 to $9.22 per share in the past 60 days, while estimates for 2027 earnings have deteriorated from $14.66 to $13.68 over the same timeframe.
ALNY Estimate Movement
Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.